Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company focused on developing therapies targeting tumor necrosis factor (TNF) superfamily receptors for inflammatory and immune-mediated conditions, announced its participation in the upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium, scheduled for February 12-13, 2026. Company executives, including CEO Taylor Schreiber, CFO Andrew R. Neill, and VP of Clinical Development Michael Choi, will engage in a fireside chat during the conference, set for February 12 at 2:00 PM ET.

The event will serve as a platform for Shattuck Labs to discuss its innovative approach and showcase its clinical pipeline, particularly focusing on SL-325, a potential first-in-class antibody targeting the Death Receptor 3 (DR3). This promising drug aims for an effective and sustained blockade of the DR3/TL1A pathway, with Shattuck’s preclinical research indicating superior efficacy compared to existing TL1A antibodies. SL-325, currently undergoing Phase 1 clinical trials, is an Fc-silenced humanized immunoglobulin G monoclonal antibody that has demonstrated a favorable safety profile in non-human primates.

Shattuck Labs is dedicated to finding solutions for conditions such as inflammatory bowel disease (IBD) and has established expertise in protein engineering, harnessing the development of novel TNF receptor therapeutics. This fireside chat at the Piper Sandler conference presents a critical opportunity for the company to connect with investors and stakeholders about its pioneering research and future directions in immunology.

A replay of the fireside chat will be made available on Shattuck's website starting February 12, 2026, at 2:00 PM ET, and will remain accessible for 30 days. For more information, stakeholders can visit www.ShattuckLabs.com.

Shattuck Labs, Inc. (NASDAQ: STTK) is at a pivotal point in its development of novel therapeutics designed to target inflammatory and immune-mediated diseases, specifically through its promising lead candidate, SL-325. As the company prepares for its participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12-13, 2026, investors should note key developments impacting the stock's trajectory.

The focus on SL-325, a first-in-class Death Receptor 3 (DR3) blocking antibody, is particularly noteworthy. The data from preclinical studies suggest its potential for superior efficacy compared to current TL1A antibodies, positioning it uniquely in a crowded market. Given the increasing prevalence of inflammatory conditions such as inflammatory bowel disease (IBD), the demand for innovative treatments is expected to grow. This provides Shattuck Labs with a strategic window to capitalize on its advancements.

Investors should pay close attention to the upcoming presentation, where company executives will likely discuss further insights into SL-325's clinical trial results and the strategic direction of the company. The projected safety profile observed in non-human primates offers an encouraging outlook for patient applications, which could propel the stock's performance should results from ongoing Phase 1 trials prove favorable.

Moreover, the biotechnology sector is characterized by volatility linked to clinical trial outcomes. Thus, while Shattuck Labs presents a compelling investment opportunity, it carries inherent risks associated with clinical-stage companies. Investors should carefully evaluate their risk tolerance and consider engaging in a diversified strategy to mitigate potential impacts from fluctuations in clinical advancements.

In summary, Shattuck Labs appears poised for growth in a vital therapeutic area within biotechnology. Attending the symposium could provide investors with valuable insights to make informed decisions, balancing the prospects of robust innovation against the inherent risks of the sector.